Free tool
FAERS Monitor: Xolair
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 103976 or its brand name (Xolair, Omalizumab). Reports on generic versions are filed under their own applications.
Reports
87,094
Serious
46,180
53% of reports
Hospitalization
15,984
Death reported
2,485
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- asthma12,359
- urticaria11,739
- no adverse event11,200
- off label use11,096
- dyspnoea10,547
- drug ineffective8,624
- cough7,188
- pruritus6,575
- fatigue6,263
- malaise5,790
- wheezing5,674
- headache5,574
- pneumonia5,462
- pain4,566
- anaphylactic reaction4,550
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 506 |
| 2005 | 528 |
| 2006 | 455 |
| 2007 | 705 |
| 2008 | 564 |
| 2009 | 864 |
| 2010 | 993 |
| 2011 | 1,196 |
| 2012 | 1,937 |
| 2013 | 1,613 |
| 2014 | 1,912 |
| 2015 | 2,180 |
| 2016 | 3,762 |
| 2017 | 7,651 |
| 2018 | 4,876 |
| 2019 | 5,460 |
| 2020 | 5,473 |
| 2021 | 5,295 |
| 2022 | 5,312 |
| 2023 | 5,719 |
| 2024 | 13,060 |
| 2025 | 9,846 |
| 2026 | 7,187 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,967,065 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| asthmaSignal | 12,359 | 29.5 | 29.0 | 305,015 |
| wheezingSignal | 5,674 | 25.4 | 24.8 | 120,820 |
| anaphylactic reactionSignal | 4,550 | 21.6 | 20.9 | 82,146 |
| urticariaSignal | 11,739 | 18.1 | 17.8 | 177,997 |
| no adverse eventSignal | 11,200 | 15.8 | 15.6 | 147,406 |
| coughSignal | 7,188 | 6.3 | 6.2 | 31,828 |
| dyspnoeaSignal | 10,547 | 4.6 | 4.5 | 29,618 |
| pruritusSignal | 6,575 | 4.2 | 4.1 | 15,961 |
| pneumoniaSignal | 5,462 | 4.1 | 4.0 | 12,918 |
| malaiseSignal | 5,790 | 3.2 | 3.1 | 8,915 |
| off label useSignal | 11,096 | 3.1 | 3.0 | 16,123 |
| headacheSignal | 5,574 | 2.2 | 2.1 | 3,534 |
| fatigue | 6,263 | 2.0 | 1.9 | 2,986 |
| pain | 4,566 | 1.8 | 1.8 | 1,662 |
| drug ineffective | 8,624 | 1.6 | 1.6 | 1,968 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.